Literature DB >> 2474093

Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects.

M H Weinberger1.   

Abstract

Angiotensin converting enzyme (ACE) inhibition has provided a new approach to the treatment of hypertension. The broad efficacy of ACE inhibitors across the entire spectrum of hypertension exceeds original predictions. Diuretics have been shown to extend efficacy to over 85% of noncomplicated hypertensives. In addition to efficacy, combination of ACE inhibitors with diuretics permits prevention or attenuation of many undesirable side effects of diuretic therapy, including hypokalemia, hyperuricemia, hyperglycemia, and hypercholesterolemia. Thus, considerations of both efficacy and beneficial effects on cardiovascular disease risk factors make the combination of ACE inhibitors and diuretics an attractive one in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474093     DOI: 10.1097/00005344-198900133-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

2.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 3.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 4.  ACE inhibitors. Differential use in elderly patients with hypertension.

Authors:  Z H Israili; W D Hall
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 5.  Hypertension-related morbidity and mortality in African Americans--why we need to do better.

Authors:  Keith C Ferdinand; Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 6.  Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician.

Authors:  Camila M Manrique; Guido Lastra; John Palmer; Craig S Stump; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 7.  Dispelling the myth of "aggressive" antihypertensive therapy.

Authors:  Elizabeth O Ofili
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

8.  Treatment of Hypertension with Combination of Lisinopril/Hydrochlorothiazide.

Authors:  Aziz Sukalo; Dervis Deljo; Amina Krupalija; Nerma Zjajo; Sabina Kos; Amela Curic; Goran Divkovic; Sabina Hubjar; Mina Smailagic; Edina Hodzic; Danijela Marjanovic; Senad Medjedovic
Journal:  Med Arch       Date:  2016-07-27

9.  Genistein Prevents Nitric Oxide Deficiency-Induced Cardiac Dysfunction and Remodeling in Rats.

Authors:  Anuson Poasakate; Putcharawipa Maneesai; Siwayu Rattanakanokchai; Sarawoot Bunbupha; Terdthai Tong-Un; Poungrat Pakdeechote
Journal:  Antioxidants (Basel)       Date:  2021-02-04

10.  Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database.

Authors:  Joel Neutel; David H G Smith
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jan-Feb       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.